In the last couple of days at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting 2024, the ...

Oncternal is halting the development of two cancer candidates, ONCT-534 and ONCT-808, after disappointing trial results.

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

No drug specifically targets the underlying pathophysiological processes that cause sepsis and only symptomatic treatments ...

CVRx’s Barostim is a baroreflex activation therapy device. Building on long-term data announced earlier this year, CVRx has ...

Alio’s SmartPatch was cleared by the US FDA to measure multiple health metrics, including clinical markers, blood pressure ...

Sanofi has reported that Phase III LIBERTY-CUPID Study C of Dupixent in patients with chronic spontaneous urticaria met ...

Viridian Therapeutics will be reporting data from a second Phase III trial of veligrotug before the end of 2024.

Mazdutide also increased hepatic fatty acids oxidation via GCG receptor signalling and decreased HbA1c levels by 3.7mmol/mol ...

Orforglipron has the potential to become the first oral glucagon-like peptide-1 receptor (GLP-1R) agonist to reach the ...

Summit shared data from the HARMONi-2 study at the World Conference on Lung Cancer (WCLC) conference in San Diego.

The prevalence and incidence rates of HIV in this community can be attributed to a wide variety of structural and behavioural ...